ArticleAnnals of medicine and surgery (2012)2026
Epinephrine nasal spray for anaphylaxis: a preferred needle-free self-treatment.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaphylaxis is a rapid-onset, potentially fatal allergic reaction that requires immediate epinephrine administration. Traditional intramuscular auto-injectors can be hindered by needle phobia, incorrect use, limited availability, and injection-related injuries. Neffy, the first FDA-approved intranasal epinephrine spray, provides a needle-free, rapid, and user-friendly alternative. Its nasal formulation allows swift absorption, producing pharmacodynamic effects within one minute, comparable to conventional auto-injectors. By eliminating needles, Neffy reduces the risk of lacerations, ischemic complications, and accidental injuries, while enhancing adherence among patients or caregivers hesitant to use injections. Early data indicate effective management of anaphylaxis with this device, though further studies in broader populations are warranted. Adoption of nasal epinephrine may improve timely treatment, increase accessibility, and offer a safer, patient-centered approach to emergency allergic reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.